Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PMS Is Important for Products Approved via Bridging Studies: PMDEC
November 5, 2001
- DIAGNOSTIC NEWS IN BRIEF
November 5, 2001
- Drug Classification Table for Selection of Comparator Drugs Approved by Chuikyo
November 5, 2001
- Yutaka Pharmacy Ties Up with Drug Lion, Reaching Sales of \50 Bil.
November 5, 2001
- Reduction in Price Adjustment Zone Below 2% Is Inappropriate: Korosho Director
November 5, 2001
- Seijo to Tie Up with Yoshioka Sante to Reach Sales of \158 Bil.
November 5, 2001
- BUSINESS NEWS IN BRIEF
November 5, 2001
- Yamanouchi Aims at Consumer Products Sales of \150 Bil. in 2005
November 5, 2001
- Shionogi, GSK Reach FinalAgreement for Joint Venture
November 5, 2001
- Prices of Medical Devices Are Secondary Matters: Mr Rozynski of AdvaMed
November 5, 2001
- Mitsubishi Chemical Safety Institute Establishes Alliance with PRXL
November 5, 2001
- MEDICAL DEVICE NEWS IN BRIEF
November 5, 2001
- NBI, Daiichi Provide Results of Immediate PMS for Mobic
November 5, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
October 29, 2001
- Drug Cost Ratio Down to 16.8% of Medical Cost for Outpatients in 1998
October 29, 2001
- Olympus Codevelops Ultrasound Surgical System with Intuitive Surgical of the US
October 29, 2001
- Glivec Recommended for Approval
October 29, 2001
- GEYMS Markets Fully-digital Ultrasound Diagnostic Equipment
October 29, 2001
- Dr Takemi, Lawmaker, Strongly Opposes Korosho, MOF Reform Plans
October 29, 2001
- Toshiba, NTT Com to Start ASP Services for Remote Imaging Diagnosis
October 29, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…